In English |
2010-09-09
Active Biotech to Present at the Rodman & Renshaw 12th Annual Healthcare Conference |
2010-08-11
Active Biotech AB Interim report January - June 2010 |
2010-07-30
Number of shares and votes in Active Biotech |
2010-06-30
Number of shares and votes in Active Biotech |
2010-06-10
Active Biotech Capital Markets Day |
2010-06-07
Active Biotech's TASQ prostate cancer project presented at ASCO |
2010-05-21
Active Biotech's TASQ prostate cancer project to be presented at ASCO |
2010-05-18
Active Biotech invites to Capital Markets Day |
2010-05-18
Active Biotech's Renal Cancer Project ANYARA Featured in Journal of Immunotherapy |
2010-05-17
Active Biotech to Present at the Rodman & Renshaw 6th Annual Global Healthcare Conference |
2010-05-17
Active Biotech's Prostate Cancer Project TASQ Featured in Molecular Cancer |
2010-05-07
Annual General Meeting of Active Biotech AB |
2010-04-30
Number of shares and votes in Active Biotech |
2010-04-22
Active Biotech AB Interim report January - March 2010 |
2010-04-20
Annual Report 2009 Active Biotech AB (publ) |
2010-04-15
NEW DATA SUGGEST ORAL LAQUINIMOD MAY CONFER NEUROPROTECTION IN ADDITION TO IMMUNOMODULATION IN THE TREATMENT OF MULTIPLE SCLEROSIS |
2010-04-06
Notice of Annual General Meeting of Shareholders |
2010-04-01
Active Biotech raises SEK 149 million through a directed share issue |
2010-03-31
Number of shares and votes in Active Biotech |
2010-02-26
Number of shares and votes in Active Biotech |
2010-02-11
Active Biotech AB Year-end Report, January - December 2009 |
2010-02-10
Exploratory data presented for Active Biotech's ANYARA project |
2010-02-10
Exploratory data presented for Active Biotech's ANYARA project |
2010-02-08
TEVA ACQUIRES MARKETING RIGHTS FOR ORAL LAQUINIMOD IN THE NORDIC AND BALTIC REGIONS |
2009-12-14
Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial in prostate cancer patients |
2009-11-05
Active Biotech's election committee appointed |
2009-11-05
Active Biotech AB Interim Report, January - September 2009 |
2009-10-05
RhuDex Clinical Development to Continue Following Feedback from Regulatory Authorities |
2009-09-25
Active Biotech's Prostate Cancer Project TASQ Featured in British Journal of Cancer |
2009-09-17
Active Biotech to Present at the UBS Global Life Sciences Conference |
2009-09-11
LAQUINIMOD IMMUNOMODULATORY ACTION CONFERS BOTH NEUROPROTECTIVE AND ANTI-INFLAMMATORY PROPERTIES |
2009-09-08
Laquinimod presentations at ECTRIMS |
2009-09-04
Active Biotech to Present at the Rodman & Renshaw 11th Annual Healthcare Conference |
2009-08-07
New information regarding RhuDex(TM) |
2009-08-06
Active Biotech AB Interim report January-June 2009 |
2009-07-28
Active Biotech's Cancer Project ANYARA Featured in Journal of Clinical Oncology |
2009-06-30
Number of shares and votes in Active Biotech |
2009-06-25
Teva Completes Enrollment in Second Oral Laquinimod Phase III MS Clinical Trial |
2009-06-15
Active Biotech's rights issue substantially oversubscribed |
2009-06-11
Active Biotech Presents Data regarding the 57-57 SLE Project at EULAR |
2009-06-08
Active Biotech Completes Patient Enrollment to TASQ Clinical Phase II study |
2009-06-01
Active Biotech Completes Patient Enrollment to ANYARA Phase III Clinical Trial |
2009-05-18
Announcement of prospectus regarding rights issue in Active Biotech AB (publ) |
2009-05-08
Annual General Meeting of Active Biotech AB |
2009-04-28
Active Biotech presents S100A9 as a target for quinoline compounds |
2009-04-28
NEW DATA ILLUSTRATE NOVEL MECHANISM OF ACTION OF LAQUINIMOD, AN ORAL COMPOUND FOR THE TREATMENT OF MULTIPLE SCLEROSIS |
2009-04-23
Active Biotech AB Interim report January-March 2009 |
2009-04-06
The Board of Active Biotech AB proposes that the Annual General Meeting resolve to make a guaranteed rights issue of approximately SEK 256 M |
2009-04-06
Notice of Annual General Meeting of Shareholders |
2009-04-06
Annual Report 2008 Active Biotech AB (publ) |
2009-02-12
Active Biotech AB year End Report January-December 2008 |
2009-02-12
ORAL LAQUINIMOD FOR MULTIPLE SCLEROSIS GRANTED FAST TRACK STATUS BY FDA |
2009-01-26
Information from Active Biotech AB's Election Committee |
2008-12-10
Active Biotech's Cancer Project ANYARA: Combination with Established Tumor Therapies Promising |
2008-11-28
Active Biotech's election committee appointed |
2008-11-18
Teva Completes Enrollment in Laquinimod Phase III Clinical Trial |
2008-11-14
Active Biotech AB Interim Report January-September 2008 |
2008-11-06
Active Biotech to Present at the Rodman & Renshaw 10th Annual Healthcare Conference |
2008-10-28
Active Biotech Presents New Data regarding the 57-57 SLE Project at American College of Rheumatology Meeting |
2008-10-17
New information regarding RhuDex® |
2008-09-18
LAQUINIMOD DEMONSTRATED SIGNIFICANT AND SUSTAINED IMPACT ON MULTIPLE SCLEROSIS DISEASE ACTIVITY |
2008-09-17
Active Biotech to Present at the UBS 2008 Global Life Sciences Conference |
2008-08-06
Active Biotech AB Interim Report January-June 2008 |
2008-07-23
Tomas Leanderson appointed new President & CEO for Active Biotech |
2008-07-16
TEVA ENROLLS PATIENTS FOR A SECOND LARGE GLOBAL PHASE III TRIAL OF ORAL LAQUINIMOD |
2008-06-30
Number of shares and votes in Active Biotech |
2008-06-24
RhuDex® Achieves Positive Results in Clinical Phase IIa Trial |
2008-06-20
Active Biotech's Novel MS Compound laquinimod Featured in the Scientific Publication The Lancet |
2008-06-12
Active Biotech's new issue fully subscribed |
2008-05-15
Active Biotech to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference |
2008-05-15
Announcement of prospectus regarding rights issue in Active Biotech AB (publ) |
2008-05-13
Active Biotech advances ANYARA into Phase III clinical trial |
2008-05-08
Annual General Meeting of Active Biotech AB |
2008-05-07
Annual Report 2007 Active Biotech AB (publ) |
2008-04-24
Active Biotech AB Interim Report January-March 2008 |
2008-04-15
Preclinical data presented for Active Biotech's ANYARA technology |
2008-04-09
Invitation to Annual General Meeting of Shareholders |
2008-04-07
The Board of Active Biotech AB proposes that the Annual General Meeting resolve to make a guaranteed rights issue of approximately SEK 160 M |
2008-02-14
Active Biotech Year-End Report January-December 2007 |
2007-11-22
Active Biotech's election committee appointed |
2007-11-08
Active Biotech Interim Report Jan-Sep 2007 |
2007-11-07
Invitation Conference Call - Active Biotech AB |
2007-11-07
INITIATION OF ENROLLMENT IN PIVOTAL PHASE III CLINICAL STUDY OF ORAL LAQUINIMOD FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS |
2007-11-01
Active Biotech to Present at the Rodman & Renshaw 9th Annual Healthcare Conference |
2007-10-24
Active Biotech's Cancer Project ANYARA Proven Safe in Combination with Taxotere® |
2007-10-02
RhuDex®; MediGene Obtains US Patent |
2007-09-20
Active Biotech to Present at the UBS 2007 Global Life Sciences Conference |
2007-08-10
FDA Approves IND for Phase II Studies of TASQ |
2007-08-09
Active Biotech Interim Report January-June 2007 |
2007-07-26
EMEA Grants Orphan Drug Status to Active Biotech's Cancer Treatment ANYARA |
2007-06-18
Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation |
2007-06-15
New positive pre-clinical data for Active Biotech's RA project I-3D |
2007-06-07
TEVA AND ACTIVE BIOTECH TO INITIATE PIVOTAL PHASE III TRIAL PROGRAM OF ORAL LAQUINIMOD FOR RELAPSING MULTIPLE SCLEROSIS |
2007-05-10
Active Biotech to Present at the Rodman & Renshaw 4th Annual Global Healthcare Conference |
2007-05-04
Active Biotech Interim Report Jan-March 2007 |
2007-05-03
Active Biotech to Present at BIO 2007 Annual International Convention |
2007-05-01
Laquinimod, a Novel Oral Compound, Showed Significant Reduction in Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) |
2007-04-20
Annual General Meeting of Active Biotech AB |
2007-03-28
Early repayment of Active Biotech's convertible loan |
2007-03-27
Active Biotech Publishes Data Regarding the TASQ Prostate Cancer Project |
2007-03-22
Invitation to Annual General Meeting of Shareholders |
2007-03-15
The Election Committee's proposal for approval by the Annual General Meeting of Active Biotech |
2007-03-13
Active Biotech's I-3D micro-dosing clinical trial concluded |
2007-03-09
Positive Clinical Data for TASQ - Active Biotech's Novel Treatment of Prostate Cancer |
2007-02-15
Active Biotech calls for premature repayment of convertible loan |
2007-02-15
Active Biotech Year-End Report 2006 |
2007-02-14
Active Biotech's new share issue oversubscribed |
2007-01-23
RhuDex® Enters Clinical Phase IIa Trial in Rheumatoid Arthritis |
2007-01-12
Active Biotech's nominations committee appointed |
2007-01-04
Active Biotech's Guaranteed Preferential Rights Issue of SEK 240 M; Correction |
2006-12-18
Active Biotech to conduct guaranteed preferential rights issue for approximately SEK 240 M |
2006-12-13
Active Biotech's Novel Cancer Treatment ANYARA Shows Pharmacological Proof of Concept after Successful Phase I Studies |
2006-11-21
Active Biotech receives 5 MSEK from VINNOVA |
2006-11-02
Active Biotech Interim Report Jan-Sep 2006 |
2006-11-01
Active Biotech to Present at the Rodman & Renshaw 8th Annual Healthcare Conference |
2006-10-09
Maria Borelius leaves the Board of Active Biotech AB |
2006-09-20
Positive clinical results for Active Biotech's prostate cancer project TASQ |
2006-09-18
Active Biotech to Present at the UBS Global Life Sciences Conference |
2006-09-07
Active Biotech publishes pre-clinical data regarding the TASQ prostate cancer project |
2006-09-05
Laquinimod Phase IIb Trial confirms efficacy and favorable safety profile and shows significant reduction in the rate of inflammatory disease activity |
2006-08-10
Active Biotech Interim Report January-June 2006 |
2006-08-08
Invitation Conference Call - Active Biotech AB |
2006-06-26
Active Biotech's project 57-57 presented at EULAR in Amsterdam |
2006-06-05
Active Biotech's ANYARA cancer project presented at ASCO in Atlanta |
2006-05-12
Active Biotech to Present at the Rodman & Renshaw |
2006-05-11
Active Biotech Interim Report January-March 2006 |
2006-05-09
ACTIVE BIOTECH AND CHELSEA THERAPEUTICS TO CO-DEVELOP PORTFOLIO |
2006-05-08
Invitation Conference Call - Active Biotech AB |
2006-04-27
Annual General Meeting of Active Biotech AB |
2006-04-04
Active Biotech at BIO 2006 |
2006-03-28
Invitation to Annual General Meeting of Shareholders |
2006-03-27
Patent application submitted regarding the mode of action for quinoline compounds |
2006-03-09
RhuDex® successfully concludes Phase I clinical trials |
2006-03-06
Active Biotech to Present at the Cowen & Company 26th Annual Health Care Conference |
2006-02-16
Active Biotech Year-end Report January-December 2005 |
2006-02-13
Invitation Teleconference - Active Biotech AB |
2006-01-16
Active Biotech's nominations committee appointed |
2005-12-19
Active Biotech Advances 57-57 Project |
2005-12-15
Active Biotech Reports Interim Results of ANYARA Phase I Clinical Trial |
2005-11-08
Active Biotech Commences Clinical Phase I Combination Study of ANYARA and Taxotere® |
2005-11-03
Active Biotech to Present at the SG Cowen & Company 6th Annual |
2005-11-02
Active Biotech Interim Report January - September 2005 |
2005-11-01
Active Biotech to Present at The Rodman & Renshaw Techvest |
2005-10-28
Invitation Teleconference - Active Biotech AB |
2005-09-30
Active Biotech presents survival data on cancer drug |
2005-09-30
Confirmed ANYARA tumor PET localization in cancer patients |
2005-09-29
Active Biotech presents survival data on cancer drug |
2005-09-29
Confirmed ANYARA tumor PET localization in cancer patients |
2005-09-27
Confirmed favorable safety profile for Active Biotech's oral MS drug |
2005-09-22
Active Biotech to present at UBS Global Life Sciences Conference |
2005-08-11
Active Biotech Interim report January - June 2005 |
2005-08-09
Invitation Teleconference - Active Biotech AB |
2005-07-18
Phase I study for Active Biotech's SLE project 57-57 successfully concluded |
2005-07-07
Active Biotech's new share issue oversubscribed |
2005-06-28
TEVA AND ACTIVE BIOTECH ANNOUNCE THE SUBMISSION OF AN IND TO THE FDA FOR LAQUINIMOD, AN ORAL PRODUCT FOR THE TREATMENT OF RELAPSING MS |
2005-06-15
Meet Active Biotech at BIO2005 Annual Convention, June 19-22 in Philadelphia, USA |
2005-05-18
Active Biotech's preferential rights issue for approximately 169 MSEK |
2005-05-12
Active Biotech Interim Report January-March 2005 |
2005-05-09
Invitation Teleconference - Active Biotech AB |
2005-05-09
RhuDex® for the treatment of RA enters Phase I clinical trials |
2005-04-29
Active Biotech to present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference |
2005-04-22
Annual General Meeting of Active Biotech AB |
2005-03-24
Invitation to Annual General Meeting of Shareholders |
2005-03-22
Teva and Active Biotech Announce That Laquinimod Phase II Data Has Been Published Today in Neurology |
2005-03-10
Active Biotech to present at SG Cowen & Co. 25th Annual Health Care Conference |
2005-02-17
Year-end report Jan-Dec 2004 |
2005-02-14
Invitation Teleconference - Active Biotech AB |
2005-02-03
Shareholder-friendly measures to promote liquidity |
2004-12-20
Active Biotech's nominations committee appointed |
2004-12-15
Convertible debentures issue fully subscribed |
2004-12-13
Active Biotech commences clinical studies in prostate cancer patients |
2004-12-02
Approved patent in the U.S. for Active Biotech's cancer project TTS |
2004-12-01
FDA has granted Fast Track Status to Active Biotech's TTS cancer project |
2004-11-15
Active Biotech to present at SG Cowen & Co 5th Annual Global Health Care Conference |
2004-11-09
Extraordinary General Meeting - Active Biotech AB |
2004-11-05
Active Biotech Interim Report January-September 2004 |
2004-11-03
Invitation Teleconference - Active Biotech AB |
2004-11-02
Active Biotech commences clinical studies for 57-57 project against SLE |
2004-10-25
Active Biotech to present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference |
2004-10-22
Announcement of debenture issue |
2004-10-22
Invitation to Extraordinary General Meeting of Shareholders |
2004-10-18
Active Biotech's Capital Market Meeting with Teva Pharmaceutical Industries in Stockholm on October 19 |
2004-09-22
Active Biotech to present at UBS Global Life Sciences Conference |
2004-09-15
Invitation to Active Biotech's capital market meeting with Teva Pharmaceutical Industries in Stockholm on October 19 |
2004-09-15
Active Biotech proposes a rights issue of convertible debentures totalling SEK 150 M |
2004-08-25
Correction of information in the magazine Affärsvärlden |
2004-08-24
FEDERAL TRADE COMMISSION CLEARS TEVA/ACTIVE BIOTECH AGREEMENT |
2004-08-12
Active Biotech - Interim report Jan-Jun 2004 |
2004-08-09
Invitation Teleconference - Active Biotech AB |
2004-06-14
TEVA AND ACTIVE BIOTECH ANNOUNCE AGREEMENT FOR LAQUINIMOD |
2004-06-03
Active Biotech AB and Strathmann Biotec AG conclude agreement regarding manufacturing of TTS cancer product |
2004-06-02
Meet Active Biotech at BIO2004 Annual Convention, June 6-9 in San Francisco, CA |
2004-05-13
Avidex and Active Biotech enter collaboration to develop fusion proteins combining monoclonal mTCRs with superantigens |
2004-05-13
Active Biotech Interim Report January-March 2004 |
2004-05-11
Invitation Teleconference - Active Biotech AB |
2004-04-27
Active Biotech at the 56th Annual Meeting of the American Academy of Neurology |
2004-04-22
Annual General Meeting of Active Biotech AB |
2004-04-02
Active Biotech - Annual Report 2003 |
2004-04-01
Active Biotech and PowderJect Pharmaceuticals have reached an amicable settlement of their arbitration |
2004-03-25
Pancreatic cancer suitable for treatment with Active Biotech's TTS cancer products |
2004-03-24
Invitation to Annual General Meeting of Shareholders |
2004-02-27
Active Biotech focuses operations on development projects |
2004-02-12
Active Biotech - Year End Report, January-December 2003 |
2004-02-09
Invitation Teleconference - Active Biotech AB |
2004-01-02
Active Biotech AB on Attract 40 |
2003-12-18
Active Biotech - the first day for trading in the new single class of shares will be December 19 |
2003-12-17
Positive results confirmed in final report for Active Biotech's TTS cancer product |
2003-12-08
Decision by Extraordinary General Meeting of Active Biotech AB (publ) |
2003-11-10
Invitation to Extraordinary General Meeting of Shareholders |
2003-11-06
Active Biotech Interim Report January - September 2003 |
2003-10-27
Positive preclinical results for Active Biotech's project 57-57 for the treatment of SLE |
2003-09-17
Active Biotech to present at UBS Global Life Sciences Conference |
2003-09-16
Invitation Teleconference - Active Biotech AB |
2003-09-16
Primary endpoint reached in Phase II clinical trial of Active Biotech's substance for oral treatment of multiple sclerosis |
2003-08-14
Active Biotech Interim Report January-June 2003 |
2003-08-11
Invitation Teleconference - Active Biotech AB |
2003-07-28
CPMP recommends registration for Dukoral in the EU |
2003-06-18
Meet Active Biotech at BIO2003 Annual Convention, June 22-25 in Washington D.C |
2003-06-12
Active Biotech rejects the claim made by PowderJect Pharmaceuticals |
2003-06-04
First day for trading in Active Biotech's newly issued B shares will be on Friday June 6, 2003 |
2003-06-02
Interim evaluation of Active Biotech's TTS CD2 for renal cancer shows encouraging results in clinical Phase IIa |
2003-05-23
Final count confirms Active Biotech's new share issue oversubscribed |
2003-05-19
Active Biotech's new share issue oversubscribed |
2003-05-15
Active Biotech Interim Report January-March 2003 |
2003-05-12
Invitation Teleconference - Active Biotech AB |
2003-05-08
Cancer-treatment substance TTS CD3 enters Phase I clinical trials in US |
2003-04-23
Indications regarding prolonged survival with Active Biotech's TTS cancer drug |
2003-04-11
Annual General Meeting of Active Biotech AB |
2003-03-13
Invitation to Annual General Meeting of Shareholders |
2003-02-13
Active Biotech - SEK 225 million (approx. 25 million) rights issue |
2003-02-13
Active Biotech Quarterly Report Oct-Dec, Full Year 2002 |
2003-02-10
Invitation Teleconference - Active Biotech AB |
2003-01-29
Positive results from preliminary clinical studies of Active Biotech's prostate cancer drug |
2003-01-15
Håkan Åström leaves the Board of Active Biotech |
2003-01-09
Application approved by the FDA for start of TTS clinical programme |
2002-11-14
Active Biotech Interim Report July-September 2002 |
2002-11-13
New date for Active Biotech’s Q3 Teleconference |
2002-11-04
Invitation Teleconference - Active Biotech AB |
2002-10-10
New results from Active Biotech’s SAIK-MS project |
2002-08-15
Active Biotech Interim Report April-June 2002 |
2002-08-12
Teleconference - Active Biotech AB |
2002-06-24
Active Biotech has selected a new Candidate Drug for the treatment of SLE |
2002-05-31
Active Biotech’s drug for the treatment of Multiple Sclerosis |
2002-05-16
Active Biotech AB, Interim Report January-March 2002 |
2002-04-19
Annual General Meeting of Shareholders in Active Biotech 18 April 2002 |
2002-04-11
Active Biotech's Phase II study of SAIK-MS has started |
2002-04-04
Active Biotech and Avidex sign Licensing Agreement |
2002-02-06
Active Biotech's application to start Phase II pancreas cancer trial approved by UK authorities |
2002-02-04
Active Biotech obtains US patent for cancer product |
2001-11-26
Active Biotech signs licensing agreement with Oxigene regarding benzamide IP |
2001-11-13
Active Biotech's application for TTS Phase II trial approved by UK authorities |
2001-10-25
Phase II clinical trial for Active Biotech's multiple sclerosis drug SAIK-MS |
2001-08-06
Active Biotech signs Letter of Intent with Avidex Ltd. |
2001-07-03
Active Biotech sells SBL Vaccin to PowderJect Pharmaceuticals |
2001-06-26
Positive results reported by Active Biotech's TTS Phase I cancer study |
2001-05-14
The Active Biotech Group Interim Report January - March 2001 |
2000-10-25
Active Biotech receives major new order for SBL Cholera Vaccine worth MSEK 11.5 |
2000-10-19
ACTIVE BIOTECH - EXTRA SHAREHOLDERS´ MEETING 19 OCTOBER 2000 |
2000-08-18
The Active Biotech Group Half-Year Accounts January - June 2000 |
2000-08-08
Active Biotech and SmithKline Beecham agree to close collaboration regarding vaccines against travellers diarrhoea |
2000-08-08
Active Biotech concludes agreement with Aventis Pasteur |
2000-08-02
Active Biotech AB accepts offer from Carl Bennet AB on shares in Lifco AB |
2000-05-26
Active Biotech Quarterly Report January - March 2000 |
2000-04-14
ACTIVE BIOTECH SHAREHOLDERS' MEETING 12 APRIL 2000 |
2000-03-29
Preliminary results from the first Phase lll-study of the ETEC-vaccine |
2000-03-15
Invitation to Annual Meeting of Shareholders |
2000-03-02
Patent for SAIK-MS approved in the USA |
2000-02-21
Active Biotech Group Annual Accounts Report January - December 1999 |
2000-02-11
The Swedish Medical Products Agency has approved for Active Biotech to expand Phase I-trials and include patients with multiple sclerosis |
2000-01-10
New production manager for Active Biotech |
1999-12-22
PRESS RELEASE |
1999-11-24
Active Biotech Group Interim Report 1 January - 30 September 1999
|
1999-11-12
Altered day regarding financial information for Active Biotech |
1999-09-24
Increased institutional ownership in Active Biotech |
1999-08-27
Half Year Report January - June 1999 |
1999-08-03
Active Biotech gets international order for cholera vaccine after recommendation from WHO |
1999-06-29
Active Biotech's drug against MS in Phase I trials 6 months ahead of plan |
1999-06-16
Active Biotech and OXiGENE enter into research collaboration within the field of inflammatory diseases |
1999-06-08
Active Biotech gains strength with a new Head of Preclinical Research |
1999-05-20
The Active Biotech Group Quarterly Report January - March 1999 |
1999-05-12
Topics from the Managing Director's Speech at the Annual General Meeting of Active Biotech |
1999-04-23
Invitation to Annual Meeting of Shareholders |
1999-03-29
Active Biotech concentrates upon cancer diagnostics |
1999-03-01
Active Biotech Group Annual Accounts Report January - December 1998 |
1999-01-15
NOVEL PRODUCT IDENTIFIED FOR TOOTH DECAY |
1998-12-29
Active Biotech acquires 100 % in Transport AB Movera |
1998-12-22
Active Biotech sells its real estate in Lund for SEK 320 M with a capital gain of SEK 80M |
1998-12-16
Sven Andréasson new President & CEO of Active Biotech |
1998-11-19
Active Biotech Group Interim Report 1 January - 30 September 1998 |
1998-11-17
BioPhausia and Active Biotech to co-operate in cancer project |
1998-09-07
SUBSTANTIAL ACQUISITION OF SHARES |
1998-07-02
Very high level of participation in Active Biotech's warrants programme for personnel |
1998-06-29
Active Biotech steps up efforts in ETEC and cholera vaccine through acquisition of VITEC |
1998-06-05
Active Biotech AB's directed new share issue fully subscribed |
1998-05-20
New issue fully subscribed |
1998-04-17
Active Biotech's Annual General Meeting approved the acquisition of the Lund Research Center |
1998-03-10
New Head of Research at Active Biotech |
1998-03-09
Active Biotech - new force in biotechnology |
1997-12-19
Active Biotech acquires Lund Research Center from Pharmacia & Upjohn |
1997-10-20
ACTIVE becomes Active Biotech - operations concentrated on biotechnology |
1997-10-05
ACTIVE to concentrate on biotechnology |
1997-05-29
Agreement with Swedish Government on acquisition of SBL Vaccin AB |
1997-05-13
SBL Vaccin acquisition approved by ACTIVE's Annual General Meeting |
1997-05-12
ACTIVE acquires SBL Vaccin AB from the Swedish State |
In Swedish |
2010-09-09
Active Biotech presenterar på Rodman & Renshaw 12th Annual Healthcare Conference |
2010-08-11
Active Biotech AB Delårsrapport januari - juni 2010 |
2010-07-30
Antal aktier och röster i Active Biotech |
2010-06-30
Antal aktier och röster i Active Biotech |
2010-06-10
Active Biotechs kapitalmarknadsdag |
2010-06-07
Active Biotechs prostatacancerprojekt TASQ presenterat på ASCO |
2010-05-21
Active Biotechs prostatacancerprojekt presenteras på ASCO |
2010-05-18
Active Biotech inbjuder till Kapitalmarknadsdag |
2010-05-18
Active Biotechs njurcancerprojekt ANYARA presenteras i Journal of Immunotherapy |
2010-05-17
Active Biotech to Present at the Rodman & Renshaw 6th Annual Global Healthcare Conference |
2010-05-17
Active Biotechs prostatacancerprojekt TASQ presenteras i Molecular Cancer |
2010-05-07
Årsstämma i Active Biotech AB |
2010-04-30
Antal aktier och röster i Active Biotech |
2010-04-22
Active Biotech AB Delårsrapport januari - mars 2010 |
2010-04-20
Årsredovisning 2009 Active Biotech AB (publ) |
2010-04-15
NYA DATA VISAR ATT LAQUINIMODS IMMUNMODULERANDE EFFEKT PÅ MULTIPEL SKLEROS ÄVEN KAN VARA NERVSKYDDANDE |
2010-04-06
Kallelse till årsstämma |
2010-04-01
Active Biotech tillförs 149 miljoner kronor genom en riktad nyemission |
2010-03-31
Antal aktier och röster i Active Biotech |
2010-02-26
Antal aktier och röster i Active Biotech |
2010-02-11
Active Biotech AB Bokslutsrapport, januari - december 2009 |
2010-02-10
Explorativa data presenterade för Active Biotechs projekt ANYARA |
2010-02-10
Explorativa data presenterade för Active Biotechs projekt ANYARA |
2010-02-08
TEVA FÖRVÄRVAR MARKNADSRÄTTIGHETERNA FÖR LAQUINIMOD I NORDEN OCH BALTIKUM |
2009-12-14
Primärt mål uppnått i klinisk fas II-prövning för Active Biotechs prostatacancerprojekt TASQ |
2009-11-05
Active Biotechs valberedning utsedd |
2009-11-05
Active Biotech AB Delårsrapport, januari - september 2009 |
2009-10-05
Det brittiska läkemedelsverket ger klartecken för fortsatt klinisk utveckling av RhuDex |
2009-09-25
Active Biotechs prostatacancerprojekt TASQ presenteras i British Journal of Cancer |
2009-09-17
Active Biotech presenterar på UBS Global Life Sciences Conference |
2009-09-11
LAQUINIMODS IMMUNMODULERANDE MEKANISM HAR BÅDE NERVSKYDDANDE OCH ANTI-INFLAMMATORISKA EGENSKAPER |
2009-09-08
Laquinimod presenteras på ECTRIMS |
2009-09-04
Active Biotech presenterar på Rodman & Renshaw 11th Annual Healthcare Conference |
2009-08-07
Ny information kring RhuDex(TM) |
2009-08-06
Active Biotech AB Delårsrapport januari-juni 2009 |
2009-07-28
Active Biotechs cancerprojekt ANYARA presenteras i Journal of Clinical Oncology |
2009-06-30
Antal aktier och röster i Active Biotech |
2009-06-25
BRAVO-studien för laquinimod fullrekryterad |
2009-06-15
Active Biotechs nyemission kraftigt övertecknad |
2009-06-11
Active Biotech presenterar data rörande SLE-projektet 57-57 på EULAR |
2009-06-08
Patientrekryteringen till Active Biotechs kliniska fas II-studie för TASQ avslutad |
2009-06-01
Patientrekryteringen till Active Biotechs kliniska fas III-studie för ANYARA avslutad |
2009-05-18
Offentliggörande av prospekt avseende nyemission i Active Biotech AB (publ) |
2009-05-08
Årsstämma i Active Biotech AB |
2009-04-28
Active Biotech presenterar S100A9 som en målmolekyl för quinolinsubstanser |
2009-04-28
NYA RÖN KRING VERKNINGSMEKANISMEN FÖR LAQUINIMOD, EN NY ORAL BEHANDLING AV MULTIPEL SKLEROS |
2009-04-23
Active Biotech AB Delårsrapport januari-mars 2009 |
2009-04-06
Styrelsen för Active Biotech AB föreslår årsstämman att besluta om en garanterad företrädesemission om cirka 256 MSEK |
2009-04-06
Kallelse till årsstämma |
2009-04-06
Årsredovisning 2008 Active Biotech AB (publ) |
2009-02-12
Active Biotech AB Bokslutsrapport januari-december 2008 |
2009-02-12
LAQUINIMOD FÖR ORAL BEHANDLING AV MULTIPEL SKLEROS ERHÅLLER FAST TRACK-STATUS FRÅN FDA |
2009-01-26
Information från Active Biotech AB:s valberedning |
2008-12-10
Active Biotechs cancerprojekt ANYARA: Kombination med etablerade tumörläkemedel lovande |
2008-11-28
Active Biotechs valberedning utsedd |
2008-11-18
Patientrekryteringen till den kliniska fas III-studien för laquinimod avslutad |
2008-11-14
Active Biotech AB Delårsrapport januari-september 2008 |
2008-10-28
Active Biotech presenterar nya data rörande SLE-projektet 57-57 på American College of Rheumatology |
2008-10-17
Ny information kring RhuDex® |
2008-09-18
LAQUINIMOD UPPVISAR SIGNIFIKANT OCH BIBEHÅLLEN VERKAN PÅ SJUKDOMEN MULTIPEL SKLEROS |
2008-09-17
Active Biotech presenterar på UBS 2008 Global Life Sciences Conference |
2008-08-06
Active Biotech AB Delårsrapport januari-juni 2008 |
2008-07-23
Tomas Leanderson ny verkställande direktör i Active Biotech |
2008-07-16
TEVA REKRYTERAR PATIENTER TILL EN ANDRA STOR GLOBAL REGISTRERINGSGRUNDANDE FAS III-STUDIE AV ORAL LAQUINIMOD FÖR BEHANDLING AV RELAPSERANDE REMITTERANDE MULTIPEL SKLEROS |
2008-06-30
Antal aktier och röster i Active Biotech |
2008-06-24
Positiva resultat för RhuDex® i klinisk fas IIa-studie |
2008-06-20
Active Biotechs orala MS-läkemedel laquinimod presenteras i den vetenskapliga tidskriften The Lancet |
2008-06-12
Active Biotechs nyemission fulltecknad |
2008-05-15
Offentliggörande av prospekt avseende nyemission i Active Biotech AB (publ) |
2008-05-13
Active Biotechs ANYARA går vidare till fas III kliniska prövningar |
2008-05-08
Årsstämma i Active Biotech AB |
2008-04-24
Active Biotech AB Delårsrapport januari-mars 2008 |
2008-04-23
Årsredovisning 2007 Active Biotech AB (publ) |
2008-04-15
Prekliniska data presenterade för Active Biotechs ANYARA-teknologi |
2008-04-09
Kallelse till årsstämma |
2008-04-07
Styrelsen för Active Biotech AB föreslår årsstämman att besluta om en garanterad företrädesemission om cirka 160 MSEK |
2008-02-14
Active Biotech Bokslutsrapport januari-december 2007 |
2007-11-22
Active Biotechs valberedning utsedd |
2007-11-08
Active Biotech Delårsrapport jan-sep 2007 |
2007-11-07
Inbjudan Telekonferens - Active Biotech AB |
2007-11-07
PATIENTREKRYTERING TILL REGISTRERINGSGRUNDANDE KLINISK FAS III-STUDIE INLEDD FÖR ORALT LAQUINIMOD FÖR BEHANDLING AV RELAPSERANDE REMITTERANDE MULTIPEL SKLEROS |
2007-11-01
Active Biotech to Present at the Rodman & Renshaw 9th Annual Healthcare Conference |
2007-10-24
Active Biotechs cancerprojekt ANYARA säkert i kombination med Taxotere® |
2007-10-02
RhuDex®; MediGene erhåller patent i USA |
2007-08-10
FDA godkänner IND för start av TASQ fas II-studier |
2007-08-09
Active Biotech Delårsrapport januari-juni 2007 |
2007-07-26
Active Biotechs cancerläkemedel ANYARA erhåller orphan drug-status av EMEA |
2007-06-18
Active Biotech presenterar nya prekliniska data för 57-57 på "8th World Congress on Inflammation" |
2007-06-15
Nya positiva prekliniska data för Active Biotechs RA-projekt I-3D |
2007-06-07
ACTIVE BIOTECH OCH TEVA INLEDER REGISTRERINGSGRUNDANDE FAS III-PRÖVNINGAR AV SITT ORALA MS-PREPARAT LAQUINIMOD |
2007-05-04
Active Biotech Delårsrapport januari-mars 2007 |
2007-05-01
Laquinimod, en ny substans i tablettform, uppvisar en signifikant minskning av sjukdomsaktiviteten i patienter med relapserande remitterande multipel skleros (RRMS) |
2007-04-20
Årsstämma i Active Biotech AB |
2007-03-28
Förtida lösen av Active Biotechs konvertibellån |
2007-03-27
Active Biotech publicerar data gällande prostatacancerprojektet TASQ |
2007-03-22
Kallelse till årsstämma |
2007-03-15
Valberedningens förslag till beslut på Active Biotechs årsstämma |
2007-03-13
Active Biotechs I-3D klinisk mikrodos-studie avslutad |
2007-03-09
Positiva kliniska data för TASQ - Active Biotechs projekt för behandling av prostatacancer |
2007-02-15
Active Biotech påkallar förtida återbetalning av konvertibellån |
2007-02-15
Active Biotech Bokslutsrapport 2006 |
2007-02-14
Active Biotechs nyemission övertecknad |
2007-01-23
RhuDex® inleder kliniska fas II-prövningar för behandling av ledgångsreumatism |
2007-01-12
Active Biotechs nomineringskommitté utsedd |
2007-01-04
Active Biotechs garanterade företrädesemission om 240 MSEK; Korrigering |
2006-12-18
Active Biotech genomför garanterad företrädesemission om cirka 240 MSEK |
2006-12-13
Active Biotechs nya cancerbehandling ANYARA uppvisar farmakologisk effekt i patienter i framgångsrika fas I-studier |
2006-11-21
Active Biotech erhåller 5 miljoner kronor från VINNOVA |
2006-11-02
Active Biotech Delårsrapport Jan-Sept 2006 |
2006-10-09
Maria Borelius lämnar styrelsen i Active Biotech AB |
2006-09-20
Positiva kliniska resultat för Active Biotechs prostatacancerprojekt TASQ |
2006-09-07
Active Biotech publicerar prekliniska data gällande prostatacancerprojektet TASQ |
2006-09-05
Fas IIb-studie bekräftar laquinimods effektivitet och fördelaktiga säkerhetsprofil samt uppvisar en signifikant minskning av inflammatorisk sjukdomsaktivitet |
2006-08-10
Active Biotech Delårsrapport Januari-Juni 2006 |
2006-08-08
Inbjudan Telekonferens - Active Biotech AB |
2006-06-26
Active Biotechs projekt 57-57 presenterat på EULAR i Amsterdam |
2006-06-05
Active Biotechs cancerprojekt ANYARA presenterat på ASCO i Atlanta |
2006-05-11
Active Biotech Delårsrapport januari-mars 2006 |
2006-05-09
ACTIVE BIOTECH OCH CHELSEA THERAPEUTICS TECKNAR SAMARBETSAVTAL |
2006-05-08
Inbjudan Telekonferens - Active Biotech AB |
2006-04-27
Bolagsstämma i Active Biotech AB |
2006-03-28
Kallelse till årsstämma |
2006-03-27
Patentansökan inskickad rörande quinolinsubstansernas verkningsmekanism |
2006-03-09
RhuDex® avslutar fas I-studier positivt |
2006-02-16
Active Biotech Bokslutsrapport januari-december 2005 |
2006-02-13
Inbjudan Telekonferens - Active Biotech AB |
2006-01-16
Active Biotechs nomineringskommitté utsedd |
2005-12-19
Active Biotech har startat klinisk prövning med patienter för projektet 57-57 |
2005-12-15
Active Biotech rapporterar interimsresultat från ANYARA fas I klinisk studie |
2005-11-08
Active Biotech inleder klinisk fas I kombinationsstudie med ANYARA och Taxotere® |
2005-11-02
Active Biotech Delårsrapport Januari-September 2005 |
2005-10-28
Inbjudan Telekonferens - Active Biotech AB |
2005-09-30
Active Biotech presenterar överlevnadsdata för cancerläkemedel |
2005-09-30
Bekräftad tumörlokalisation av ANYARA hos cancerpatienter med hjälp av PET |
2005-09-29
Active Biotech presenterar överlevnadsdata för cancerläkemedel |
2005-09-29
Bekräftad tumörlokalisation av ANYARA hos cancerpatienter med hjälp av PET |
2005-09-27
Fördelaktig säkerhetsprofil bekräftad för Active Biotechs orala MS-läkemedel |
2005-08-11
Active Biotech AB Delårsrapport Januari-juni 2005 |
2005-08-09
Inbjudan Telekonferens - Active Biotech AB |
2005-07-18
Fas I-studie positivt avslutad för Active Biotechs SLE-projekt 57-57 |
2005-07-07
Active Biotechs nyemission övertecknad |
2005-06-28
TEVA OCH ACTIVE BIOTECH LÄMNAR IN IND-ANSÖKAN TILL FDA FÖR LAQUINIMOD; EN ORAL PRODUKT FÖR BEHANDLING AV RELAPSERANDE MS |
2005-05-18
Active Biotechs företrädesemission om cirka 169 MSEK |
2005-05-12
Active Biotech Delårsrapport januari-mars 2005 |
2005-05-09
Inbjudan Telekonferens - Active Biotech AB |
2005-05-09
RhuDex för behandling av RA inleder fas I kliniska prövningar |
2005-04-29
Active Biotech presenterar på Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference |
2005-04-22
VDs anförande vid Active Biotechs bolagsstämma 2005 |
2005-04-22
Bolagsstämma i Active Biotech AB |
2005-03-24
Kallelse till bolagsstämma |
2005-03-22
Teva och Active Biotech meddelar att laquinimod fas II-data har publicerats idag i Neurology |
2005-03-10
Active Biotech presenterar på SG Cowen & Co. 25th Annual Health Care Conference |
2005-02-17
Bokslutsrapport jan-dec 2004 |
2005-02-14
Inbjudan Telekonferens - Active Biotech AB |
2005-02-03
Likviditetsfrämjande och aktieägarvänliga åtgärder |
2004-12-20
Active Biotechs nomineringskommitté utsedd |
2004-12-15
Emissionen av konvertibla förlagsbevis i Active Biotech fulltecknad |
2004-12-13
Active Biotech inleder kliniska studier i patienter med prostatacancer |
2004-12-02
Godkänt patent i USA för Active Biotechs cancerprojekt TTS |
2004-12-01
FDA har beviljat Fast Track-status för Active Biotechs cancerprojekt TTS |
2004-11-15
Active Biotech presenterar på SG Cowen & Co 5th Annual Global Health Care Conference |
2004-11-09
Extra bolagsstämma - Active Biotech AB |
2004-11-05
Active Biotech Delårsrapport januari-september 2004 |
2004-11-03
Inbjudan Telekonferens - Active Biotech AB |
2004-11-02
Active Biotech inleder kliniska studier för projekt 57-57 för SLE |
2004-10-22
Kungörelse av emissionsbeslut |
2004-10-22
Kallelse till extra bolagsstämma |
2004-10-18
Active Biotechs kapitalmarknadsmöte med Teva Pharmaceutical Industries i Stockholm den 19 oktober |
2004-09-15
Inbjudan till Active Biotechs kapitalmarknadsmöte med Teva Pharmaceutical Industries i Stockholm den 19 oktober |
2004-09-15
Active Biotech föreslår nyemission av konvertibler om cirka 150 Mkr |
2004-08-25
Rättelse av uppgifter i tidningen Affärsvärlden |
2004-08-24
FEDERAL TRADE COMMISSION GODKÄNNER AVTAL MELLAN TEVA OCH ACTIVE BIOTECH |
2004-08-12
Active Biotech - Delårsrapport januari-juni 2004 |
2004-08-09
Inbjudan Telekonferens - Active Biotech AB |
2004-06-14
TEVA OCH ACTIVE BIOTECH SLUTER AVTAL KRING LAQUINIMOD FÖR ORAL BEHANDLING AV MULTIPEL SKLEROS |
2004-06-03
Active Biotech AB och Strathmann Biotec AG tecknar avtal för produktion av cancerprodukten TTS |
2004-05-13
Active Biotech tecknar samarbetsavtal med Avidex Ltd för utveckling av fusionsprotein med monoklonala TCR och superantigen |
2004-05-13
Active Biotech Delårsrapport januari-mars 2004 |
2004-05-11
Inbjudan Telekonferens - Active Biotech AB |
2004-04-27
Active Biotech vid 56th Annual Meeting of the American Academy of Neurology |
2004-04-22
Bolagsstämma i Active Biotech AB |
2004-04-02
Active Biotech - Årsredovisning 2003 |
2004-04-01
Active Biotech och Chiron har enats om en förlikning i skiljedomsförfarandet |
2004-03-25
Active Biotechs cancerprodukt TTS verksam för behandling av pankreascancer |
2004-03-24
Kallelse till bolagsstämma |
2004-02-27
Active Biotech fokuserar verksamheten mot projekt i klinisk fas |
2004-02-12
Active Biotech - Bokslutsrapport, januari-december 2003 |
2004-02-09
Inbjudan Telekonferens - Active Biotech AB |
2004-01-15
Ingen relation till Biometron AB |
2004-01-02
Active Biotech på Attract 40 |
2003-12-18
Active Biotech - handel med ett enda aktieslag inleds den 19 december |
2003-12-17
Positiva resultat konfirmerade i slutrapport för Active Biotechs cancerprodukt TTS |
2003-12-08
Beslut från extra bolagsstämma Active Biotech AB (publ) |
2003-11-10
Kallelse till extra bolagsstämma |
2003-11-06
Active Biotech Delårsrapport januari - september 2003 |
2003-10-27
Positiva prekliniska resultat för Active Biotechs projekt 57-57 för behandling av SLE |
2003-09-16
Inbjudan Telekonferens - Active Biotech AB |
2003-09-16
Active Biotechs orala substans för behandling av multipel skleros uppnår primärt mål i klinisk fas II-prövning |
2003-08-14
Active Biotech Delårsrapport Januari-Juni 2003 |
2003-08-11
Inbjudan Telekonferens - Active Biotech AB |
2003-07-25
CPMP rekommenderar registrering i EU för Dukoral |
2003-06-12
Active Biotech avvisar krav från PowderJect Pharmaceuticals |
2003-06-04
Första dag för handel i Active Biotechs nyemitterade B-aktier blir fredagen den 6 juni 2003 |
2003-06-02
Interimsutvärdering av Active Biotechs TTS CD2 mot njurcancer visar lovande resultat i klinisk Fas IIa |
2003-05-23
Slutlig sammanräkning bekräftar överteckning i Active Biotechs nyemission |
2003-05-19
Active Biotechs nyemission övertecknad |
2003-05-15
Active Biotech Delårsrapport januari-mars 2003 |
2003-05-12
Inbjudan Telekonferens - Active Biotech AB |
2003-05-08
Cancerpreparatet TTS CD3 i Fas I klinisk studie i USA |
2003-04-23
Indikationer avseende förlängd överlevnad med Active Biotechs TTS- cancerpreparat |
2003-04-11
Bolagsstämma i Active Biotech AB |
2003-03-13
Kallelse till bolagsstämma |
2003-02-13
Active Biotech - Företrädesemission om 225 Mkr |
2003-02-13
Active Biotech Kvartalsrapport, Okt-Dec 2002, samt helår |
2003-02-10
Inbjudan Telekonferens - Active Biotech AB |
2003-01-29
Positiva resultat från inledande kliniska studier av Active Biotechs prostatacancer-preparat |
2003-01-15
Håkan Åström lämnar styrelsen i Active Biotech |
2003-01-09
Ansökan godkänd av FDA för start av kliniskt prövningsprogram för cancerprojektet TTS |
2002-11-13
Active Biotech Kvartalsrapport Juli-September 2002 |
2002-11-13
Ny tid för Active Biotechs Q3 telefonkonferens |
2002-11-08
Ändrat datum för Active Biotechs Q3-rapport |
2002-11-04
Inbjudan Telekonferens - Active Biotech AB |
2002-08-15
Active Biotech Kvartalsrapport April-juni 2002 |
2002-08-12
Telekonferens - Active Biotech AB |
2002-06-24
Active Biotech har valt läkemedelskandidat för SLE-projektet |
2002-05-31
Active Biotechs läkemedel mot multipel skleros |
2002-05-16
Active Biotech AB, Kvartalsrapport januari-mars 2002 |
2002-05-15
Active Biotech Telefonkonferens, Q1 |
2002-04-19
Bolagsstämma i Active Biotech AB den 18 april 2002 |
2002-04-11
Active Biotechs Fas II-studie av SAIK-MS har inletts |
2002-04-04
Active Biotech och Avidex tecknar licensavtal |
2002-02-06
Active Biotechs ansökan godkänd av engelska myndigheter för start av Fas II pankreascancer studie |
2002-02-04
Active Biotech får patent i USA för cancerprodukt |
2001-11-26
Active Biotech tecknar licensavtal med Oxigene kring benzamidpatent |
2001-11-13
Active Biotechs ansökan om klinisk prövning Fas II godkänd av brittiska myndigheter |
2001-10-25
Fas II klinisk prövning för Active Biotechs läkemedel mot MS |
2001-08-06
Active Biotech tecknar nytt samarbetsavtal |
2001-07-03
Active Biotech säljer SBL Vaccin till PowderJect Pharmaceuticals |
2001-06-26
Positiva resultat från Active Biotechs TTS Fas I cancerstudie |
2001-05-09
Active Biotech-koncernen Kvartalsrapport januari-mars 2001 |
2001-02-15
Active Biotech-koncernen Bokslutskommuniké för verksamhetsåret 2000 |
2000-11-16
Active Biotech-koncernen: Delårsrapport januari - september 2000 |
2000-10-24
Active Biotech erhåller ny stor order på SBL Cholera Vaccine, värd 11,5 mkr |
2000-10-19
EXTRA BOLAGSSTÄMMA - ACTIVE BIOTECH 19 OKTOBER 2000. |
2000-08-17
Active Biotech-koncernen Halvårsbokslut januari - juni 2000 |
2000-08-08
Active Biotech och SmithKline Beecham avtalar om att avsluta samarbetet kring vaccin mot turistdiarré |
2000-08-08
Active Biotech tecknar avtal med Aventis Pasteur |
2000-08-02
Active Biotech AB accepterar Carl Bennet ABs bud på aktier i Lifco AB |
2000-05-25
Active Biotech Kvartalsrapport januari - mars 2000 |
2000-04-13
Flaggningsmeddelande |
2000-04-13
ACTIVE BIOTECHS BOLAGSTÄMMA 12 APRIL 2000 |
2000-04-13
MGA Holding ny storägare i Active Biotech AB |
2000-04-13
Bo Håkanssons inledningsanförande vid Active Biotechs bolagsstämma 2000-04-12 |
2000-03-29
Preliminära resultat från Fas III-studier av ETEC-vaccinet |
2000-03-15
Kallelse till bolagsstämma |
2000-02-29
Patent för SAIK-MS beviljat i USA |
2000-02-18
Bokslutskommuniké januari - december 1999 |
2000-02-11
Läkemedelsverket har godkänt att Active Biotech genomför en utvidgad Fas I-prövning som även inkluderar patienter med sjukdomen multipel skleros |
1999-12-22
Ny produktionschef till Active Biotech |
1999-12-21
PRESSRELEASE |
1999-11-22
Active Biotech-koncernen Delårsrapport 1 januari - 30 september 1999 |
1999-11-12
Ändrad rapportdag för Active Biotech |
1999-09-24
Ökat institutionellt ägande i Active Biotech |
1999-08-26
Active Biotech-koncernen Halvårsbokslut januari - juni 1999 |
1999-08-02
Active Biotech får internationell order på koleravaccin efter rekommendation av WHO |
1999-06-28
Active Biotechs läkemedel mot MS 6 månader tidigare i fas I |
1999-06-16
Active Biotech och OXiGENE inleder forskningssamarbete inom området inflammation |
1999-06-07
Active Biotech förstärker med ny preklinisk forskningschef |
1999-05-31
Notering av aktierna i Wilh. Sonesson AB (publ) på O-listan vid Stockholms Fondbörs |
1999-05-17
Active Biotech-koncernen Kvartalsrapport januari - mars 1999 |
1999-05-11
Många nyheter i VD-talet på Active Biotechs bolagsstämma |
1999-04-29
Tidplan för utdelning av Wilh. Sonesson AB |
1999-04-23
Kallelse till Bolagsstämma |
1999-04-22
Årsredovisning 1998 |
1999-03-29
Active Biotech satsar på cancerdiagnostik |
1999-02-25
Bokslutskommuniké januari - december 1998 |
1998-12-28
Active Biotech forvärvar 100 % i Transport AB Movera |
1998-12-22
Active Biotech säljer sin fastighet i Lund for 320 mkr med en realisationsvinst på 80 mkr |
1998-12-16
Sven Andréasson ny VD i Active Biotech |
1998-11-19
Delårsrapport 1 januari - 30 september 1998 |
1998-11-17
BioPhausia och Active Biotech i samarbete om cancerprojekt. |
1998-09-07
FLAGGNINGSMEDDELANDE |
1998-07-02
Mycket stor anslutning till Active Biotechs personaloptioner |
1998-06-29
Active Biotech ökar satsningen på ETEC- och koleravaccin genom förvärv av Vitec |
1998-06-05
Active Biotech ABs riktade nyemission fulltecknad |
1998-05-20
Nyemissionen fulltecknad |
1998-04-17
Active Biotechs bolagsstämma godkände förvärvet av Lund Research Center |
1998-04-02
Active Biotech renodlar - säljer Rederi AB Heron. Soliditeten ökar från 34% till 49%.
|
1998-03-31
Nyemissioner i Active Biotech |
1998-03-10
Ny forskningschef i Active Biotech |
1998-03-09
Active Biotech ny kraft inom bioteknik |
1998-02-26
Bokslutskommuniké för 1997 |